Related Experiment Video
Updated: May 3, 2026
10:04
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
Published on: August 1, 2025
1.9K
Dendritic cells and cancer immunotherapy
Kristen J Radford1, Kirsteen M Tullett2, Mireille H Lahoud3
1Mater Research Institute, University of Queensland, Translational Research Institute, Brisbane, Australia; University of Queensland, School of Biomedical Sciences, Brisbane, Australia.
Current Opinion in Immunology
|February 12, 2014
Summary
Dendritic cells (DCs) are crucial for anti-cancer immunity. Targeting specific DC subsets, like CD141(+) DCs, shows promise for developing more effective cancer vaccines with improved anti-tumour responses.
Area of Science:
- Immunology
- Cancer Research
- Vaccinology
Background:
- Dendritic cells (DCs) are vital for initiating and regulating immune responses, including anti-cancer immunity.
- While DC-based cancer vaccines are generally safe, their clinical efficacy remains limited.
- Recent research highlights the significant role of CD141(+) DCs in anti-tumour immune responses.
Purpose of the Study:
- To explore the potential of targeting specific dendritic cell (DC) subsets for enhanced cancer vaccine development.
- To investigate strategies for improving the delivery of tumour antigens to DCs and boosting immune responses.
- To leverage the understanding of DC subset specializations for more effective cancer immunotherapy.
Main Methods:
- Review of recent studies on dendritic cell subsets and their role in anti-tumour immunity.
- Analysis of strategies for antigen delivery to DCs.
- Evaluation of methods for enhancing immune responses against cancer.
Main Results:
- CD141(+) DCs have been identified as key players in anti-tumour immune responses.
- Targeting DCs in vivo presents an attractive strategy for novel cancer vaccine design.
- Understanding DC functional specializations is crucial for optimizing vaccine efficacy.
Conclusions:
- Targeting CD141(+) dendritic cells (DCs) offers a promising strategy for advancing DC-based cancer vaccines.
- Improved antigen delivery and immune response enhancement are critical for future vaccine development.
- Further research into DC subset functions will drive the creation of more effective cancer immunotherapies.
Related Concept Videos
01:27Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
01:30Cancer Vaccines
1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
01:27Cytotoxic T Cells-mediated Immune Response
7.0K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.0K
01:22T Cell Activation and Clonal Selection
13.7K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
13.7K
02:40Cancer Stem Cells and Tumor Maintenance
4.3K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.3K
01:40Cell-mediated Immune Responses
64.7K
Overview
64.7K